Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
| Autor: | Francis Ali-Osman, Robert B. Livingston, Mitchel S. Berger, Alexander M. Spence, Brian R. Griffin |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Neurology medicine.medical_treatment Gastroenterology Internal medicine Glioma medicine Humans Infusions Intravenous Cisplatin Chemotherapy Brain Neoplasms business.industry Astrocytoma Middle Aged medicine.disease Surgery Clinical trial Oncology Tumor progression Vomiting Drug Evaluation Female Neurology (clinical) Neoplasm Recurrence Local medicine.symptom business Nitroso Compounds medicine.drug |
| Zdroj: | Journal of Neuro-Oncology. 12 |
| ISSN: | 1573-7373 0167-594X |
| DOI: | 10.1007/bf00172671 |
| Popis: | Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink